170355-78-9
170355-78-9
Chemical Structure
CD2665
- CAS. Nr.: 170355-78-9
- Formula:C31H34O5
- Molecular Weight:486.60
IUPAC Name: 4-(7-((3r,5r,7r)-adamantan-1-yl)-6-((2-methoxyethoxy)methoxy)naphthalen-2-yl)benzoic acid
InChIKey: JBALRFFXKQPVLT-BUPRXJOYSA-N
SMILES: COCCOCOC1=CC2=CC=C(C3=CC=C(C(O)=O)C=C3)C=C2C=C1C45C[C@H](C6)C[C@H](C[C@H]6C5)C4
Biological Activity: CD2665 is an orally active and selective RAR-β,γ antagonist, with Kd values of 306 nM, 110 nM for RAR-β and RAR-γ, repectively[1][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CD2665 | 99.68% | CD2665 is an orally active and selective RAR-β,γ antagonist, with Kd values of 306 nM, 110 nM for RAR-β and RAR-γ, repectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kim MJ, et al. The role of specific retinoid receptors in sebocyte growth and differentiation in culture. J Invest Dermatol. 2000 Feb;114(2):349-53. [Content Brief]
- [3]. Koyama E, et al.Premature Growth Plate Closure Caused by a Hedgehog Cancer Drug Is Preventable by Co-Administration of a Retinoid Antagonist in Mice. J Bone Miner Res. 2021 Jul;36(7):1387-1402. [Content Brief]
